Cargando…

P469: ACUTE MYELOID LEUKEMIA DRIVES BCL-2 UPREGULATION IN NON MALIGNANT HSPCS WHICH IS TARGETED BY VENETOCLAX AND CAUSES CYTOPENIA

Detalles Bibliográficos
Autores principales:	Fowler-Shorten, Dominic, Maynard, Rebecca, Hampton, Katherine, Ehikioya, Martha, De Silva, Ravindu, Bowles, Kristian, Rushworth, Stuart, Hellmich, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429043/ http://dx.doi.org/10.1097/01.HS9.0000968784.32685.51

Ejemplares similares

P856: MULTIPLE MYELOMA DERIVED IL-6 REDUCES FATTY ACID METABOLISM IN THE LIVER BY DOWNREGULATING CD36 AND CPT1A IN HEPATOCYTES
por: Egheose Ehikioya, Martha, et al.
Publicado: (2023)

P423: ACUTE MYELOID LEUKEMIA REPROGRAMS LIPID METABOLISM BY DOWNREGULATING CD36 EXPRESSION IN HEPATOCYTES.
por: Maynard, Rebecca, et al.
Publicado: (2023)

P431: ACTIVATION OF MACROPHAGE STING ENHANCES PHAGOCYTOSIS OF ACUTE MYELOID LEUKAEMIA
por: Maynard, Rebecca, et al.
Publicado: (2023)

Refractory Autoimmune Cytopenias Treated With Venetoclax
por: Gordon, Max J., et al.
Publicado: (2019)

P1341: LC3-ASSOCIATED PHAGOCYTOSIS IS IMPAIRED IN BONE MARROW MACROPHAGES DURING AGEING LEADING TO DEFECTIVE PHAGOCYTOSIS AND ACCUMULATION OF APOPTOTIC DEBRIS WITHIN THE BONE MARROW.
por: Hampton, Katherine, et al.
Publicado: (2023)

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
por: Mistry, Jayna J, et al.
Publicado: (2021)

Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche
por: Maynard, Rebecca S., et al.
Publicado: (2022)

ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia
por: Hellmich, Charlotte, et al.
Publicado: (2020)

PB1846: MANAGEMENT OF PATIENTS TREATED WITH VENETOCLAX WITH HYPOMETHYLATING AGENTS: LONG-TERM INCIDENCE OF CYTOPENIAS AND INFECTIONS
por: Guardia-Torrelles, Ares, et al.
Publicado: (2023)

Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression
por: Ning, Na, et al.
Publicado: (2022)

Answer to the question from page 469
Publicado: (2013)

P1401: UNBIASED, LONGITUDINAL ANALYSIS OF THE INFLAMMATORY RESPONSE OF HSPCS AT THE SINGLE CELL LEVEL RESOLVES CONTROVERSIES REGARDING THE HSPCS STRESS RESPONSE
por: Demerdash, Y., et al.
Publicado: (2022)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Copper Levels in Patients with Unexplained Dysplastic Cytopenia
por: Butcher, Dominic, et al.
Publicado: (2020)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
por: Guarente, Valerio, et al.
Publicado: (2021)

Fungal Planet description sheets: 469–557
por: Crous, P.W., et al.
Publicado: (2016)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Polymorphism rs13334190 in zinc finger protein 469 (ZNF469) is not a risk factor for keratoconus in a Saudi cohort
por: Kalantan, Hatem, et al.
Publicado: (2017)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

Campylobacter Jejuni and Cytopenias
por: Schattner, Ami
Publicado: (2013)

Cytopenias in Transplant Patients
por: Barry, Maura, et al.
Publicado: (2018)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
por: Birkinshaw, Richard W., et al.
Publicado: (2019)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34(+) HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin
por: Lamsfus-Calle, Andrés, et al.
Publicado: (2020)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

Cytopenia in adult brucellosis patients
por: Kaya, Safak, et al.
Publicado: (2018)

Cytopenia associated with copper deficiency
por: Uchino, Kaori, et al.
Publicado: (2021)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
por: Chong, Stephen Jun Fei, et al.
Publicado: (2023)

HSPCs display within-family homogeneity in differentiation and proliferation despite population heterogeneity
por: Tak, Tamar, et al.
Publicado: (2021)

DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age
por: Urbanus, Jos, et al.
Publicado: (2023)

Mecom mutation related to radioulnar synostosis with amegakaryocytic thrombocytopenia reduces HSPCs in mice
por: Nagai, Koki, et al.
Publicado: (2023)

Autoimmune Cytopenias In Common Variable Immunodeficiency
por: Podjasek, Jenna C., et al.
Publicado: (2012)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
por: D'Arena, Giovanni, et al.
Publicado: (2013)

Autoimmune cytopenias in chronic lymphocytic leukemia
por: Haider, M. Shabih, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q9b5hsmblp5939eomjrt2hh826